Novo Nordisk sales beat estimates, but the story wasn’t Ozempic

• Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump

  Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
  
  CNBC - 1h

• Chipotle earnings beat estimates, but stock falls on weak same-store sales forecast

  Chipotle earnings beat estimates as restaurant traffic rises again.
  
  CNBC - 14h

• Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off

  The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.
  
  CNBC - 16h
• 

  Novo Nordisk Foundation Will Not Fill Funding Gaps

  Global health experts have questioned how philanthropies could mitigate Trump’s freeze on foreign health aid.
  
  Inc. - 1d

• FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

  Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
  
  CNBC - Jan. 28

• Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.

  Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
  
  MarketWatch - Jan. 24

• Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact

  At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss ...
  
  MarketWatch - Jan. 8

More from MarketWatch

• DeepSeek and tariffs have roiled the market. History shows deeper pullbacks are coming, this strategist says.

  Don’t be tempted to buy on these headline-driven stock-market dips, bigger opportunities are coming, says Truist’s Keith Lerner.
  
  MarketWatch - 7m

• Walmart reportedly cutting jobs as it refocuses on Bentonville headquarters

  Some employees being asked to relocate as U.S.’s largest private employer builds up hubs in Arkansas and California
  
  MarketWatch - 18m

• Oil prices drop on rising U.S. inventories and fears tariffs will dent Chinese demand

  Oil futures fell Wednesday, feeling pressure after industry data showed a large rise in U.S. crude inventories and as investors feared a U.S. -China trade battle will dent demand.
  
  MarketWatch - 24m

• Tesla sales are diving in Germany and across Europe too

  Tesla sales have careened lower in Germany in January, as sales of the electric vehicle company headed by Elon Musk tumble across Europe.
  
  MarketWatch - 25m

• Pay attention to what junk bonds are saying about the value of Treasury bonds

  High-yield bond holders aren’t asking for much of a premium above ultra-safe U.S. Treasurys. Time to own quality.
  
  MarketWatch - 28m

More in Business

• USPS temporarily suspends some inbound packages from China, Hong Kong

  The change comes after President Donald Trump announced new tariffs that also target a popular trade loophole, called "de minimis."
  
  CNBC - 3m

• Disney tops quarterly profit estimates, but starts to lose Disney+ streaming subscribers

  The company's streaming business reported another quarter of profitability despite a 1% decline in subscribers for Disney+.
  
  CNBC - 5m

• DeepSeek and tariffs have roiled the market. History shows deeper pullbacks are coming, this strategist says.

  Don’t be tempted to buy on these headline-driven stock-market dips, bigger opportunities are coming, says Truist’s Keith Lerner.
  
  MarketWatch - 7m

• Walmart reportedly cutting jobs as it refocuses on Bentonville headquarters

  Some employees being asked to relocate as U.S.’s largest private employer builds up hubs in Arkansas and California
  
  MarketWatch - 18m

• Homebuyer mortgage demand drops further, a troubling sign for the spring market

  Homebuyers are seeing very little reason to get a jump on the all-important spring housing market, even with more listings coming up for sale.
  
  CNBC - 21m